

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_84631
Title of the Manuscript:	Bio-Analytical Method Development and Validation of Avelumab, Axitinib and its Application to Pharmacokinetic Studies In Rabbit Plasma By Using UPLC
Type of the Article	Original Research Article

### General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

**Review Form 1.6**

**PART 1:** Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<p><b>The following observations were made and advised the author to respond to the following comments before its publication.</b></p> <p>1. The length of the title of research article is too long there by advised to change the title of research article as "Assay of bio analytical method for the estimation of Avelumab and Axitinib using UPLC and its application to Pharmacokinetic studies."</p> <p>2. In abstract, the results of limits of precision accuracy and recovery data shall be given.</p> <p>3. In references section some of the references are found which are not as per author guidelines. It shall be revised.</p> <p>4. Parameters like LLQC,LQC,MQC,HQC their full forms to be mentioned in the text.</p> <p>5. Mention DOI number at the end of reference for available references</p> <p>6. List the first six authors followed by et al-(Reference section )</p> <p>7. Indicate structural formulas of Avelumab, and Axitinib at the end of introduction.</p>	
<b><u>Minor</u></b> REVISION comments	-	
<b><u>Optional/General</u></b> comments	<p><b>Specific observations:</b> The following figures shall be reflected in the text. Fig.1and Fig. 2 - Structures of Avelumab, and Axitinib at the end of introduction. Remaining fig no to be changed and shall be indicated in the text</p> <p>Author mentioned fig. 5 in the text under sub heading -In Vivo Pharmacokinetic Evaluation. But fig 4 indicates -Recovery plots of (A) Avelumab and (B) Axitinib. Give justification to fig.5....?</p>	

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>Manikya Sastry</b>
Department, University & Country	<b>Gayatri Vidya Parishad College of Engineering (A), India</b>